Skip to content

A Novel Biofeedback for Urinary Incontinence in Women

A Novel Biofeedback Device to Improve Adherence to Pelvic Floor Muscle Training in Women With Urinary Incontinence: A Randomized Controlled Pilot Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04638348
Enrollment
51
Registered
2020-11-20
Start date
2020-02-01
Completion date
2021-09-29
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinence

Keywords

Biofeedback

Brief summary

A three-armed randomized pilot trial will be conducted with 51 women having stress urinary incontinence, to evaluate the acceptance and ease of use of the conventional electromyography (EMG) biofeedback via vaginal probe in the treatment of urinary incontinence and that of the newly developed EMG biofeedback with Bluetooth. Women will be randomly allocated to one of two intervention groups (new biofeedback or conventional biofeedback) or the control group (PFMT alone). Women in the intervention groups will perform PFMT either with the new biofeedback or the conventional biofeedback, based on their group allocation. The control group will perform PFMT without a biofeedback device. Study outcome measures include, feasibility measures, International Consultation on Incontinence Questionnaire, and 1-hour pad test.

Detailed description

Objectives: (1) to compare the acceptance and ease of use of the conventional electromyography (EMG) biofeedback via vaginal probe in the treatment of urinary incontinence and that of the newly developed EMG biofeedback with Bluetooth; (2) to investigate the effects of conventional biofeedback, the new biofeedback, and pelvic floor muscle training (PFMT) alone on urinary incontinence and adherence to PFMT. Hypotheses: (1) The new biofeedback will be easier to use and women will more readily accept it than the conventional biofeedback. (2) Women assigned to the new biofeedback group will report better adherence to PFMT and greater improvements in urinary incontinence than women assigned to participate in the conventional biofeedback group. Design and subjects: A three-armed randomized pilot trial will be conducted with 51 women who have stress urinary incontinence. Interventions: Women will be randomly allocated to one of two intervention groups (new biofeedback or conventional biofeedback) or the control group (PFMT alone). Women in the intervention groups will perform PFMT either with the new biofeedback or the conventional biofeedback, based on their group allocation. The control group will perform PFMT without a biofeedback device. Outcome measures: Feasibility measures, International Consultation on Incontinence Questionnaire, and 1-hour pad test. Data analysis and expected results: A one-way between-groups analysis of covariance will be conducted. Adherence to PFMT will be better in the new biofeedback group than in the conventional biofeedback group. New biofeedback will have greater beneficial effects on urinary incontinence than either the conventional biofeedback or PFMT alone.

Interventions

DEVICENew Biofeedback

Conventional biofeedback consists of a electromyography biofeedback device with a vaginal probe.

Sponsors

Kwong Wah Hospital
CollaboratorOTHER
The Hong Kong Polytechnic University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
35 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* women in the age group of 35 to 60 years of age; * non-pregnant; * having stress urinary incontinence; * experiencing mild to moderate urinary incontinence (obtaining a score of ≤ 12 on the short-form of the International Consultation on Incontinence Questionnaire (ICIQ-sf); and * obtaining a mini-mental state examination (MMSE) score of ≥ 24.

Exclusion criteria

* being in the postpartum stage of \< 6 months; * having severe pelvic organ prolapse (stages 3 and 4 on the Baden and Walker grading tool); * women taking any medications that might cause urine retention; * women having complicated UI due to radiation to pelvic region; * obesity with a body mass index ≥ 30; * women with incontinence secondary to other medical conditions or previous surgeries; * women with severe psychological problems impairing participation in the study; and * women having mixed or urge UI.

Design outcomes

Primary

MeasureTime frameDescription
Recruitment rateAt the end of recruitment periodNumber of participants recruited/screened in a week, the time taken for recruitment of participants, and reasons for declining to participate will be recorded.
AdherencePost-intervention at 6 monthsThe 0-10-point scale of the reliable tool (Cronbach's α=0.7059) developed to monitor long-term adherence to PFMT in women with UI (that quantifies adherence to home exercise as low, moderate, or high) will be used to evaluate adherence to PFMT with and without the biofeedback device
Retention ratePost-treatment at 1, 3 and 6 monthsThis will be calculated as the percentage of participants who completed assessments at 1, 3, and 6 months.

Secondary

MeasureTime frameDescription
International Consultation on Incontinence Questionnaire-short formBaseline (pre-intervention), post-treatment at 1, 3 and 6 monthsMeasures amount of urine loss and intensity. Higher score indicates more sever urinary incontinence.
one-hour pad test with stress testBaseline (pre-intervention), post-treatment at 1, 3 and 6 monthsMeasure amount of urine leakage. Larger the amount of urine lost in grams, greater is the severity of urinary incontinence.
Modified Oxford scaleBaseline (pre-intervention), post-treatment at 1, 3 and 6 monthsTo grade pelvic floor muscle strength. Lower the score, lower the strength of the pelvic floor muscles.

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026